Tirzepatide
FDA-approved dual GLP-1/GIP agonist. The gold-standard weight loss peptide with proven clinical results.
Last updated: May 2026
Category
Weight Loss (GLP-1/GIP)
Frequency
Once weekly injection
Research
FDA Approved (Mounjaro/Zepbound)Quick answer
- What is tirzepatide and what does it do?
- A once-weekly dual GIP/GLP-1 receptor agonist (sold as Mounjaro and Zepbound) that suppresses appetite and improves blood sugar. SURMOUNT-1 showed an average 22.5% weight reduction over 72 weeks, the strongest result of any approved GLP-1.
- How do you dose it?
- The FDA-approved label uses a gradual step-up: 2.5mg weekly for the first 4 weeks, then 5mg, 7.5mg, and 10mg, with a labeled maintenance range of 10 to 15mg. The GIP action makes it easier on the stomach than pure GLP-1 drugs. Those are the label figures, not a recommendation; the starting dose and how fast to step up are decided by a licensed prescriber for the individual.
- Where do you get it in Vietnam and what does it cost?
- Brand pens (Mounjaro) run roughly 5 to 7 million VND through hospital pharmacies like Vinmec and FV; research-grade vials run 2 to 3.5 million VND via cold-chain importers. Full Vietnam sourcing guide, or the vetted supply route.
What is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly and sold commercially as Mounjaro (for type 2 diabetes) and Zepbound (for obesity). It was FDA approved in 2022, making it the best-studied weight loss peptide with the most extensive clinical safety data.
The SURMOUNT-1 clinical trial demonstrated an average weight reduction of 22.5% (up to 26.6% in the highest dose group) over 72 weeks: results that had never been seen with any pharmaceutical or peptide before Retatrutide. It rapidly became the most prescribed weight loss medication in the United States.
In Vietnam, research-grade tirzepatide is available at a fraction of the cost of branded Mounjaro. For users who want proven results with strong safety data and would prefer the next step up from semaglutide, tirzepatide is typically the first recommendation. If you want to map the titration steps against expected results before you start, a clinical breakdown of tirzepatide dosing walks through each stage in detail. Browse all weight loss peptide options to compare.
How It Works
GLP-1 Agonism: Activates GLP-1 receptors to suppress appetite, slow gastric emptying, improve insulin secretion, and reduce blood sugar. This is the same receptor targeted by Semaglutide (Ozempic).
GIP Agonism: GIP receptors in adipose tissue and the brain appear to work synergistically with GLP-1 to enhance the appetite-suppressing effects. GIP agonism also appears to reduce some of the GLP-1-induced nausea, giving Tirzepatide a better tolerability profile than pure GLP-1 agonists.
Together these two mechanisms produce metabolic effects significantly greater than either alone: a phenomenon called receptor co-agonism.
The co-agonism advantage showed up directly in head-to-head data. In the SURPASS-2 trial, tirzepatide produced larger reductions in HbA1c and body weight than semaglutide in patients with type 2 diabetes, which is the clearest reason most reference sources rank it above pure GLP-1 drugs. If you are weighing the two molecules, the semaglutide reference page covers the single-receptor approach side by side.
Beyond appetite and glucose, the dual mechanism has been studied in adjacent areas. The SURMOUNT-OSA trial reported reduced obstructive sleep apnea severity in adults with obesity, which research attributes to the weight reduction itself rather than a separate airway effect. This is one reason tirzepatide is described as a metabolic-disease drug rather than a narrow weight-loss agent.
Benefits
- 22.5% average weight reduction in SURMOUNT-1 trial
- FDA approved with extensive Phase 3 clinical safety data
- Better GI tolerability vs Semaglutide (due to GIP co-agonism)
- Improved glycemic control for diabetic and pre-diabetic users
- Cardiovascular risk reduction (ongoing trials)
- Once-weekly dosing
- Strong appetite suppression with reduction in food cravings
Dosing Described in Research and Labels
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Starting | 2.5mg | Once weekly | Weeks 1 to 4 |
| Titration 1 | 5mg | Once weekly | Weeks 5 to 8 |
| Titration 2 | 7.5mg | Once weekly | Weeks 9 to 12 |
| Titration 3 | 10mg | Once weekly | Weeks 13 to 16 |
| Maintenance | 10 to 15mg | Once weekly | Ongoing |
These figures summarise what published research and approved labels describe. They are educational, not a recommendation or a personal protocol. Any dose, schedule, or decision to use a compound belongs with a licensed prescriber.
Side Effects
Common
- âš Nausea (most common, typically mild with proper titration)
- âš Diarrhea
- âš Vomiting (usually during dose increases)
- âš Constipation
- âš Decreased appetite
- âš Injection site reactions
Rare
- •Pancreatitis (rare but serious: seek immediate medical attention)
- •Gallbladder disease
- •Hypoglycemia (mainly in diabetics on insulin)
- •Acute kidney injury (from dehydration due to GI side effects)
Who Should NOT Use Tirzepatide
- ✕Personal or family history of medullary thyroid carcinoma (MTC)
- ✕Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- ✕History of severe pancreatitis
- ✕Type 1 diabetes
- ✕Pregnancy or breastfeeding
- ✕Severe gastrointestinal disease including gastroparesis
What to Expect
Mild nausea common. Appetite starts to reduce. Most users lose 1 to 3kg from water weight and reduced caloric intake.
Nausea typically resolved. Steady weight loss begins. Food cravings significantly reduced. Energy usually stable.
Consistent 0.5 to 1.5kg/week loss when combined with reasonable diet. Body composition clearly changing. Clothes fitting differently.
Weight loss slows as you approach a lower set point. Maintenance dose identified. Many users plateau around their new metabolic equilibrium.
Notes from Ho Chi Minh City
Tirzepatide is the GLP-1 most HCMC expats look to after semaglutide stalls, and the dual GIP plus GLP-1 mechanism is why the food-noise reduction the literature describes is sharper than on semaglutide. The muscle-sparing angle is the part that matters for anyone training, and it is trial data that supports it rather than anecdote, with resistance training the consistently cited co-factor for holding lean mass. On the Vietnam market, Mounjaro brand pens at Vinmec Central Park run 5 to 7 million VND each, the upper end of the local GLP-1 brand range, which pushes a fair number of people in An Phu and Thao Dien toward research-grade vials through cold-chain importers at roughly half that. The approved label titrates from a low starting dose upward on a fixed schedule; what that schedule should be for a given person is a prescriber's decision, not a default to copy.
Sourcing in Vietnam
Tirzepatide is available in Vietnam in two forms: brand pens (Mounjaro, Zepbound) at hospital pharmacies including Vinmec Central Park and FV Hospital (5 to 7 million VND per Mounjaro pen, prescription required), and research-grade vials through cold-chain importers (2 to 3.5 million VND per 10mg vial). See the Tirzepatide Vietnam 2026 guide for the full sourcing comparison.
FAQ
Q: Is generic Tirzepatide the same as Mounjaro?
A: The active molecule is identical. The difference is that branded Mounjaro goes through strict pharmaceutical manufacturing and regulatory oversight. Research-grade Tirzepatide varies in quality by supplier, which is why COA verification matters. See the full Mounjaro vs research-grade comparison for Vietnam buyers.
Q: Should I choose Tirzepatide or Retatrutide?
A: Tirzepatide has superior clinical safety data and is FDA approved. Retatrutide shows higher weight loss (~6% more) but is still in Phase 3. For your first GLP-1 experience, Tirzepatide or Semaglutide is usually recommended.
Q: What if I plateau on Tirzepatide?
A: Plateaus are common after 3 to 6 months, and the factors usually discussed are dose, training, and protein. The approved label allows stepping up within its maintenance range, resistance training helps preserve lean mass, and adequate protein supports it; whether and how to change a dose is a prescriber decision. Some people also discuss switching to Retatrutide for additional metabolic effect.
Q: Can I take Tirzepatide and BPC-157 together?
A: Yes, many users combine GLP-1 peptides with healing peptides like BPC-157. There are no known negative interactions. BPC-157 may even help with GI side effects from Tirzepatide.
Q: Is Tirzepatide actually better than Semaglutide, or is that marketing?
A: It holds up in trial data, not just marketing. The SURPASS-2 head-to-head study reported greater HbA1c and weight reduction on tirzepatide than on semaglutide in type 2 diabetes, and the GIP co-agonism is also linked to better stomach tolerability. The trade-off is cost and, in Vietnam, less consistent brand availability.
Q: How long does a course of Tirzepatide usually run?
A: Most reference protocols treat it as an ongoing weekly therapy rather than a fixed cycle, because appetite signaling tends to rebound after stopping. The research framing is maintenance over a set point, not a short course. Any decision to start, continue, or stop should be made with a clinician who knows your history.
Where to Get Tirzepatide in Vietnam
Mounjaro is intermittently available at major Vietnamese pharmacies and international hospitals; Zepbound is not registered with the DAV. For full Vietnam pricing, hospital routes, and research-grade supplier verification, see our Tirzepatide Vietnam 2026 guide. For the legal framework around peptides in Vietnam, see our legality guide. Then browse the community-verified supplier list.
Related Peptides
Related Guides
Research & Sources
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial) · Jastreboff AM, Aronne LJ, Ahmad NN, et al. · New England Journal of Medicine (2022) PMID: 35658024
SURMOUNT-1 trial showing 22.5% mean weight loss at 72 weeks on tirzepatide 15mg weekly.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2 trial) · Frias JP, Davies MJ, Rosenstock J, et al. · New England Journal of Medicine (2021) PMID: 34170647
Head-to-head SURPASS-2 trial showing tirzepatide superiority over semaglutide for HbA1c and weight reduction.
- The dual GIP and GLP-1 receptor agonist tirzepatide: pharmacology, mechanisms, and clinical impact · Coskun T, Sloop KW, Loghin C, et al. · Molecular Metabolism (2018) PMID: 30293909
Foundational pharmacology paper describing the dual-agonist mechanism.
- Tirzepatide for Sleep Apnea in Adults with Obesity (SURMOUNT-OSA trial) · Malhotra A, Grunstein RR, Fietze I, et al. · New England Journal of Medicine (2024) PMID: 38912654
SURMOUNT-OSA trial demonstrating efficacy in obstructive sleep apnea reduction.
Important Disclaimer
Educational content only. Not medical advice. Peptides discussed on this page are not approved by Vietnam’s Ministry of Health (Bộ Y Tế) or the Drug Administration of Vietnam (DAV) for the indications described. Research peptides are not stocked at Long Châu, Pharmacity, or any retail pharmacy in Vietnam. Consult a licensed physician before any use.